Sarepta Closes Enrollment in Elevidys Phase 3 Trial, Leaving Non-Ambulatory Duchenne Patients Dependent on a 25-Person Safety Study
· techtimes.com · popularity 20/100 · 0 similar stories today
Read the original at techtimes.com →
Summary
Sarepta ends ENVISION after three Elevidys deaths. Non-ambulatory Duchenne patients now depend on a 25-person sirolimus safety study and Q1 2027 FDA engagement.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 6.